Nursing · Independent exam preparation
Certified Pediatric Hematology Oncology Nurse (CPHON®) Study Guide
Practise pediatric hematology oncology decisions: recognize emergencies, interpret treatment response, manage toxicities, and coordinate family-centered nursing care.
By CertMedbry · Updated 28 October 2026
Build the judgment to distinguish treatment toxicity from urgent deterioration, interpret hematology and oncology findings, and choose supportive care that fits a child's developmental needs. This selective guide develops 60 concepts across the six CPHON domains, with clinical applications, common errors, original questions, and recall cards. The official ONCC Test Content Outline defines the full examination scope; these concepts provide a focused foundation for studying that broader scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which credential and nursing level does this guide address?
CPHON® means Certified Pediatric Hematology Oncology Nurse, issued by the Oncology Nursing Certification Corporation. It validates specialty knowledge associated with basic pediatric hematology oncology nursing practice. It is an RN specialty certification. AOCNP® addresses advanced practice in adult oncology; OCN®, TCTCN™, CBCN®, and ROCN™ have separate specialty scopes and examinations.
How many questions are scored, and which item styles are verified?
The CPHON examination contains 165 multiple-choice questions: 125 scored questions and 40 unscored pretest or experimental questions. Candidates cannot identify the unscored questions. Each item has four answer options and one correct answer. ONCC states that its tests use generic drug names.
2026 ONCC Certification Test Registration Manual · Certified Pediatric Hematology Oncology Nurse (CPHON®) | ONCC
How long is the examination session?
The 2026 manual specifies a three-hour test session, including 15 minutes for a computer-based tutorial before the examination and a post-test survey. There are no scheduled breaks, and the timer continues during an unscheduled break. Interpret the three hours as the session allowance rather than assuming three uninterrupted hours for answering questions.
How is the examination delivered, and is adaptive testing established?
The manual describes computer-based testing at PSI test centers. Testing is available year-round in the United States, its territories, and Canada, subject to appointment availability and authorization. The verified format specifies 165 questions; it does not establish computer-adaptive delivery or alternate item formats. These learning questions are independent single-best-answer drills.
Which blueprint dates apply to this guide?
Alignment uses the 2026 ONCC Certification Test Registration Manual, marked valid January 1, 2026, and the outline currently linked from ONCC's preparation page. That outline has a 2025 filename and copyright 2024, without a separately printed effective date. The manual's validity date is distinct from an outline-specific effective date. The earlier outline explicitly labeled Effective 2023 is historical comparison.
Prepare for test | ONCC · 2026 ONCC Certification Test Registration Manual · CPHON Test Content Outline — currently linked standalone PDF · CPHON Test Content Outline — Effective 2023
What are the official domain weights?
Care Continuum accounts for 6%; Pediatric Hematology and Oncology Nursing Practice, 18%; Treatment Modalities and Side Effects, 21%; Symptom Management and Supportive Care, 26%; Pediatric Hematologic and Oncologic Emergencies, 21%; and Psychosocial Dimensions of Care, 8%. The current manual and linked outline enumerate six domains. Their six-domain structure resolves the examination webpage's conflicting reference to five subject areas.
2026 ONCC Certification Test Registration Manual · CPHON Test Content Outline — currently linked standalone PDF · Certified Pediatric Hematology Oncology Nurse (CPHON®) | ONCC
How do eligibility and jurisdiction affect the pathway?
The standard initial pathway requires an active, unencumbered RN license in the United States, its territories, or Canada, together with the specified RN experience, pediatric hematology or oncology practice, and continuing education. The manual separately describes equivalency evaluation for candidates licensed elsewhere and a limited international testing period. Those provisions do not create a different CPHON examination. Confirm current arrangements with ONCC before planning international testing.
How should this guide and its practice results be used?
Use the official outline to identify the complete scope, then use these concepts and questions to expose reasoning gaps. The 60 concepts allocate 4, 11, 13, 15, 12, and 5 entries across the six domains. Each 20-item question and flashcard set allocates 1, 4, 4, 5, 4, and 2 entries. These small sets approximate the published weights and do not predict examination performance.
Prepare for test | ONCC · 2026 ONCC Certification Test Registration Manual
This independent educational guide addresses ONCC's Certified Pediatric Hematology Oncology Nurse credential for registered nurses practicing pediatric hematology/oncology. It follows the six-domain blueprint in the 2026 registration manual and currently linked outline. Clinical references support care principles; the blueprint establishes examination scope.
Outline used: Blueprint verified against the 2026 ONCC Certification Test Registration Manual, marked valid January 1, 2026, and ONCC's currently linked CPHON Test Content Outline, whose filename contains 2025 and whose copyright year is 2024. The linked outline does not state a separate effective date. The workbook label 'Pediatric Hematology Oncology Nurse (CPHON)' maps to the official Certified Pediatric Hematology Oncology Nurse examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Care Continuum6%
1.What makes a survivorship handoff clinically useful?
A survivorship handoff connects the child's treatment history with future care responsibilities. The treatment summary identifies diagnoses, therapies, relevant exposures, and complications; the follow-up plan translates those details into individualized surveillance and health maintenance. Primary care remains important alongside specialty follow-up. The discriminating question is whether the receiving clinician can identify what happened, what risks remain, and who will address them, rather than merely knowing that treatment has ended.
Apply it
A teenager transfers to a community clinician after leukemia treatment. Provide the treatment summary and individualized follow-up plan, identify the oncology contact, and clarify responsibility for routine preventive care and exposure-related surveillance before the transfer.
Common pitfall: A discharge statement saying only that the child is in remission omits the exposures and assigned follow-up responsibilities needed to support safe ongoing care.
2.How do long-term effects differ from late effects?
Long-term effects begin during treatment and continue after therapy ends, whereas late effects first appear months or years afterward. The distinction concerns timing, not necessarily severity. Both can affect physical function, learning, emotional health, and participation in ordinary activities. A symptom-free interval does not remove exposure-related risk. Follow-up therefore combines attention to persistent problems with surveillance for conditions that have not yet become clinically apparent in the individual survivor.
Apply it
One survivor has neuropathy that began during chemotherapy; another develops hearing difficulty years later. Classify the first as a persistent long-term effect and investigate the second as a possible late effect using each treatment history.
Common pitfall: Do not call every post-treatment problem a late effect. Establish when it began and assess other possible causes before attributing it to cancer therapy.
3.Why should survivor surveillance follow treatment exposures?
Children with the same cancer diagnosis can receive different therapies and acquire different late-effect risks. Exposure-based follow-up links surveillance to actual agents, radiation fields, doses, and other relevant treatment details. Anthracycline exposure and platinum exposure, for example, raise different cardiac and auditory concerns. Diagnosis alone cannot select the complete follow-up plan. New symptoms require clinical evaluation even when they occur between planned surveillance visits or outside an expected screening schedule.
Apply it
Two leukemia survivors request identical follow-up schedules. Review their individual treatment summaries first; one received an anthracycline and the other did not. Explain why their cardiac surveillance needs may differ despite the shared diagnosis.
Common pitfall: A normal current examination does not erase exposure-related risk. Conversely, a screening schedule should never postpone evaluation of a new concerning symptom.
Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0 · Care for Childhood Cancer Survivors | NCI
4.When can palliative care accompany cancer treatment?
Palliative care addresses symptoms, distress, communication, and quality of life throughout serious illness. It can accompany treatment intended to cure or control cancer, so referral does not require treatment failure or an imminent death. Hospice has a different end-of-life focus and eligibility framework. The nursing decision is driven by unmet needs: persistent pain, difficult symptoms, family distress, or complex goals can justify palliative involvement while disease-directed therapy continues for the child.
Apply it
A child receiving curative therapy has uncontrolled nausea and a family overwhelmed by repeated admissions. Introduce palliative care as additional symptom and communication support while the oncology treatment plan remains active and continues to be evaluated.
Common pitfall: Waiting until all anticancer options end can prolong avoidable distress. Palliative consultation does not itself establish a decision to stop disease-directed treatment.
Pediatric Hematology and Oncology Nursing Practice18%
5.Why can leukemia cause pallor, bruising, and infection together?
Leukemic proliferation can interfere with normal marrow production, producing combinations of anemia, thrombocytopenia, and impaired effective host defense. Pallor and reduced stamina suggest anemia; bruising or petechiae suggest platelet deficiency; fever may indicate infection. Bone pain can accompany marrow involvement. The meaningful clue is the pattern across blood-cell functions rather than any isolated symptom. A circulating white-cell count alone does not establish that the child has adequate functional infection protection.
Apply it
A school-age child has fatigue, unexplained bruising, fever, and leg pain. Recognize a possible marrow disorder and support prompt medical assessment and blood testing rather than treating the complaints as unrelated minor childhood problems.
Common pitfall: An elevated white-cell count can be falsely reassuring. Numerous abnormal circulating cells do not provide the same infection defense as an adequate population of functioning neutrophils.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI
6.Which factor deficiencies distinguish hemophilia A and B?
Hemophilia A involves deficient factor VIII activity; hemophilia B involves deficient factor IX activity. Both impair coagulation and can cause prolonged bleeding, deep-tissue bleeding, and joint hemorrhage. Clinical severity relates to the remaining factor activity, so the diagnostic label alone does not describe an individual's bleeding risk. Joint warmth, pain, swelling, or limited movement are important clues. Confirm the factor deficiency before assuming that apparently similar bleeding disorders require interchangeable replacement products.
Apply it
A parent says a child with hemophilia B should receive the same factor product as a cousin with hemophilia A. Explain the factor IX versus factor VIII distinction and verify the child's documented treatment plan.
Common pitfall: Similar bleeding manifestations do not make factor VIII and factor IX interchangeable. A normal-looking external skin examination also does not exclude internal joint bleeding.
7.How do hemolysis and vaso-occlusion differ in sickle cell disease?
Sickle cell disease can produce both shortened red-cell survival and obstruction of small blood vessels by poorly deformable cells. Hemolysis contributes to chronic anemia, whereas vaso-occlusion reduces tissue perfusion and can cause pain and organ injury. These processes coexist but explain different findings. A familiar baseline hemoglobin does not exclude a new perfusion emergency. Evaluate the location and character of symptoms, oxygenation, neurological status, and changes from the child's usual condition.
Apply it
A child with a usual low hemoglobin develops sudden severe limb pain without a major hemoglobin change. Recognize that vaso-occlusive pain can occur independently of a dramatic new anemia and assess for associated complications.
Common pitfall: Do not use the hemoglobin value as the sole measure of sickle cell severity. Vascular obstruction and organ injury may develop without a large additional decline.
Sickle Cell Disease — How Sickle Cell Disease May Affect Your Health | NHLBI
8.What does measurable residual disease add to leukemia assessment?
Measurable residual disease, or MRD, identifies leukemia below the detection capability of routine morphological examination. Flow cytometry and molecular methods can detect small residual populations that influence risk assessment and treatment decisions. Morphological remission and MRD negativity therefore answer different questions. Interpret an MRD result alongside the specimen, assay, sensitivity, and treatment time point. A negative result means disease was not detected within that test's capability; it does not prove that every leukemic cell has disappeared.
Apply it
A marrow report shows morphological remission but detectable MRD after induction. Explain that the results can coexist because the MRD assay detects smaller leukemic populations, and communicate the finding for protocol-based risk assessment and treatment planning.
Common pitfall: Calling morphological remission equivalent to absence of residual leukemia overlooks assay sensitivity and can misrepresent why additional or modified treatment remains necessary for the child.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI
9.Which findings make an abdominal mass concerning for Wilms tumor?
Wilms tumor is a childhood renal malignancy that may present as an abdominal lump or increasing abdominal size. Hematuria and hypertension provide additional renal clues, but their absence does not exclude the diagnosis. A child can have a substantial mass before appearing seriously ill. Assess blood pressure and urinary symptoms and support prompt imaging and diagnostic evaluation. The symptom pattern identifies a reason for investigation; it cannot distinguish all renal and other abdominal tumors by examination alone. See the [NCI Wilms tumor summary](https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq).
Apply it
A caregiver notices increasing abdominal fullness while dressing a preschooler who otherwise plays normally. Obtain blood pressure and a history of urinary changes and arrange prompt medical assessment rather than waiting for pain or constitutional illness.
Common pitfall: Normal activity and absence of visible blood in urine do not exclude a renal tumor. An abdominal mass requires diagnostic evaluation even when the child appears comfortable.
CPHON Test Content Outline — currently linked standalone PDF
10.Why does a leukemia genomic finding not automatically establish inherited risk?
Genomic testing of leukemic cells characterizes abnormalities relevant to the malignancy, including changes that help classify disease or identify treatment targets. Such findings can be acquired in the cancer cells rather than inherited throughout the child's body. Germline predisposition is a separate question requiring appropriate evaluation. The discriminating cue is what tissue was tested and why. Explain the clinical purpose of the result without assigning hereditary implications that the test itself has not established.
Apply it
A parent interprets a fusion identified in leukemic marrow as proof that siblings inherited the same abnormality. Clarify that tumor-cell testing and hereditary-risk evaluation address different questions, and arrange further explanation of the specific result.
Common pitfall: Treating every cancer-associated genetic abnormality as inherited can create unnecessary family alarm and inappropriate assumptions about relatives who have not undergone a relevant evaluation.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI
11.When should focal bone symptoms prompt evaluation for a bone tumor?
Osteosarcoma can produce focal bone or joint pain, swelling, stiffness, a limp, or difficulty walking. A fracture without an adequate explanation is another concerning presentation. Persistent focal symptoms with a changing examination deserve assessment rather than repeated attribution to ordinary activity. Imaging helps characterize the lesion; histological diagnosis requires planned tissue sampling. These findings also occur in other conditions, so they support investigation rather than a diagnosis based on symptoms alone. See the [NCI osteosarcoma summary](https://www.cancer.gov/types/bone/patient/osteosarcoma-treatment-pdq).
Apply it
An adolescent's knee-region pain persists and is now accompanied by swelling and a limp. Communicate the progression and support diagnostic evaluation instead of continuing to assume an uncomplicated sports injury.
Common pitfall: An athletic history does not establish a mechanical cause. Reassess the explanation when focal pain persists, swelling appears, or function declines.
CPHON Test Content Outline — currently linked standalone PDF
12.What distinguishes the main phases of therapeutic clinical trials?
Trial phase describes the principal research question. Phase I studies emphasize safety, adverse effects, and treatment administration; phase II studies evaluate activity while continuing safety assessment; phase III studies compare a promising approach with an established approach. Phase IV follows approval to gather additional information. These labels do not guarantee individual benefit or dictate every design feature. Education should connect the child's actual protocol to its purpose, procedures, alternatives, and uncertainties rather than relying on the phase name alone.
Apply it
A family assumes a phase I study has already proved the treatment works better than standard care. Explain its primary safety purpose, then review the protocol's stated potential benefits, risks, alternatives, and required visits with them.
Common pitfall: Do not equate a later phase with guaranteed benefit or describe every early-phase study as having identical goals, eligibility, or chances of helping a participant.
13.How do medication safeguards and professional accountability prevent a fatal vincristine route error?
Vincristine is for intravenous administration only and can be fatal by other routes, particularly intrathecal administration. Its label directs dilution in a flexible plastic container with a prominent intravenous-only warning to reduce route errors. Verify the specific drug, order, route, labeled preparation, and intravenous access before administration; resolve discrepancies before proceeding. Administration requires personnel experienced with vincristine. When ALL care also includes intrathecal treatment, identify each drug and route separately: a treatment protocol's use of intrathecal chemotherapy never authorizes intrathecal vincristine.
Apply it
Vincristine and intrathecal methotrexate are scheduled on the same day, and a handoff describes both only as chemotherapy. Stop the ambiguous handoff, verify each preparation and route, and ensure the vincristine container carries its intravenous-only warning before administration.
Common pitfall: A correct patient and dose do not compensate for an incorrect route. Proceeding despite an unresolved order or preparation discrepancy abandons a critical administration safeguard.
DailyMed - VINCRISTINE SULFATE injection, solution · Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI · CPHON Test Content Outline — currently linked standalone PDF
14.How is informed consent maintained during a clinical trial?
Informed consent is an ongoing communication process, not merely a signed document. Participants and families need understandable information about purpose, procedures, risks, potential benefits, alternatives, and the ability to withdraw. Important new information may require further discussion during participation. Ethical review provides oversight but does not eliminate risk. Nursing assessment should identify misunderstanding, coercion, or unanswered questions and bring these concerns to the research team before proceeding with research-specific activities requiring valid permission.
Apply it
A parent signed consent weeks ago but now believes withdrawal would end all medical care. Pause the discussion of the next research procedure and clarify voluntary participation, treatment alternatives, and the distinction between research and ongoing care.
Common pitfall: A signature does not demonstrate continuing understanding. Approval by an ethics committee also does not guarantee that a study is risk-free or suitable for every child.
15.When should a child's assent be addressed in research?
Children who can understand relevant information should receive developmentally appropriate explanations and opportunities to express willingness to participate, according to the protocol and applicable requirements. Assent complements the required parental or guardian permission; it is not simply a child's signature on adult language. The nurse assesses understanding and questions, uses appropriate communication, and reports reluctance. Legal consent rules vary, so age alone should not be used to invent a universal jurisdiction-independent consent threshold.
Apply it
A protocol requires assent from a capable adolescent who says the study is confusing. Arrange a plain-language discussion of participation and alternatives before enrollment proceeds, even though the parent has already provided permission for the research.
Common pitfall: Parental enthusiasm does not substitute for required assent. Conversely, research assent should not be presented as identical to every jurisdiction's rules for legal medical consent.
Treatment Modalities and Side Effects21%
16.How does hydroxyurea reduce sickle cell complications?
Hydroxyurea increases fetal hemoglobin and reduces red-cell sickling, helping decrease painful episodes and complications such as acute chest syndrome. Its purpose extends beyond treating pain already present during a crisis. Benefit depends on sustained prescribed use and follow-up rather than intermittent use only when symptoms occur. Explain the preventive mechanism in accessible language and distinguish improvement in disease burden from cure. The child still needs an emergency plan for fever, respiratory symptoms, and neurological changes.
Apply it
A parent stops hydroxyurea whenever the child feels well. Explain that regular treatment helps reduce future sickling complications, explore practical adherence barriers, and reconnect the family with the prescribed monitoring and medication plan.
Common pitfall: Fewer pain episodes do not mean the underlying disease has disappeared. Preventive therapy does not make new fever, chest symptoms, or focal neurological findings safe to observe.
17.Why must osteosarcoma biopsy and mobility precautions be planned before definitive surgery?
Osteosarcoma treatment generally combines systemic chemotherapy with complete surgical resection. Biopsy placement can affect later limb preservation: a poorly placed tract or contamination of surrounding tissue can compromise an otherwise feasible operation. Orthopedic oncology evaluation should therefore precede biopsy. Tumors in weight-bearing bones also require prescribed protective weight bearing to reduce pathological-fracture risk. Limb preservation depends on achieving appropriate tumor margins, not simply preserving the limb at any cost. See the [NCI surgical treatment guidance](https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq).
Apply it
An adolescent awaiting biopsy of a suspected femoral osteosarcoma asks to walk unassisted. Confirm the orthopedic team's weight-bearing restrictions and biopsy plan, provide appropriate mobility support, and explain how these precautions protect future surgical options.
Common pitfall: Biopsy is part of the oncologic surgical plan. Treating it as an interchangeable minor procedure or allowing unrestricted loading of weakened bone can jeopardize later treatment.
CPHON Test Content Outline — currently linked standalone PDF
18.Why must coagulation therapy match the diagnosed deficiency?
Hemophilia treatment aims to improve the deficient clotting function and prevent or control bleeding. Factor VIII replacement addresses hemophilia A, whereas factor IX replacement addresses hemophilia B; other therapies have specific indications and limitations. Product selection therefore follows the documented diagnosis and individual treatment plan. Bleeding history, severity, and treatment response matter. A nurse should verify what the product does rather than assuming that all treatments described as clotting therapy can substitute for one another.
Apply it
Before treatment for a painful swollen joint, the nurse finds that the ordered product does not match the documented hemophilia type. Clarify the discrepancy with the treatment team before administration while maintaining urgent assessment of the bleed.
Common pitfall: The word factor on a product label is insufficient verification. Different factor deficiencies and treatment strategies require different products and cannot be treated as interchangeable.
19.Why does ALL treatment continue after induction remission?
Induction seeks remission, but subsequent treatment addresses residual leukemia and reduces relapse risk. Childhood ALL regimens use multiple phases, commonly including consolidation or intensification and maintenance, with details determined by disease subtype and protocol. Normalization of visible findings does not establish elimination of all malignant cells. Explain each phase by its purpose rather than portraying continued therapy as evidence that induction failed. The distinction between remission and completion of therapy is essential for sustained adherence and realistic expectations.
Apply it
A family asks to stop treatment because the marrow shows remission after induction. Explain that later phases target disease not necessarily visible by routine examination and reduce recurrence risk, then review the child's actual protocol schedule.
Common pitfall: Remission is not permission to omit subsequent prescribed phases. Conversely, continued treatment after remission does not by itself indicate that the initial phase was unsuccessful.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI
20.Why does ALL therapy include central nervous system treatment?
The central nervous system can act as a sanctuary site for leukemia, so ALL treatment includes CNS-directed therapy to prevent or treat involvement. Approaches can include intrathecal and CNS-active systemic chemotherapy, with radiation reserved for selected circumstances. A normal neurological examination does not establish that preventive CNS treatment is unnecessary. The specific regimen depends on protocol and disease features. Intrathecal therapy uses designated agents; vincristine remains intravenous only because intrathecal administration can be fatal.
Apply it
A child without headaches is scheduled for intrathecal therapy. Explain the sanctuary-site rationale and verify the prescribed intrathecal agent. If vincristine is also scheduled, identify it separately as intravenous treatment and preserve its route safeguards.
Common pitfall: Absence of neurological symptoms does not remove the need for protocol-directed CNS therapy. The presence of intrathecal drugs in an ALL regimen never makes vincristine safe by that route.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI · DailyMed - VINCRISTINE SULFATE injection, solution
21.How can a genomic target change ALL treatment?
Some leukemia abnormalities identify treatment targets as well as prognostic information. BCR::ABL1-positive ALL, for example, can be treated with a tyrosine kinase inhibitor as part of a disease-specific regimen. The target supports a particular mechanism-based approach; it does not make all targeted medicines equivalent or remove the need for other protocol components. The nurse connects the identified abnormality with the prescribed drug's purpose and checks understanding of how that medicine fits the overall treatment plan.
Apply it
A parent asks why a targeted oral medicine was added after genomic results returned. Explain that the identified leukemia abnormality provides a specific target and that the medicine forms part of the child's combined treatment strategy.
Common pitfall: Targeted does not mean free of adverse effects or sufficient as the only treatment. A target found in one leukemia does not justify the same drug for another.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI
22.What distinguishes autologous from allogeneic transplantation?
Autologous transplantation returns the patient's own previously collected blood-forming stem cells, whereas allogeneic transplantation uses cells from another person. The source changes immune relationships: an allogeneic graft can provide a graft-versus-leukemia effect but can also cause graft-versus-host disease. These donor immune effects are not expected from a conventional autologous transplant. The distinction does not make autologous treatment risk-free; conditioning, infection, and delayed blood-cell recovery remain important concerns requiring substantial supportive care.
Apply it
A family preparing for autologous transplantation asks whether the child's donor sibling must be tested. Explain that the planned graft uses the child's own collected cells, then review risks relevant to conditioning and blood-cell recovery.
Common pitfall: Avoid transferring donor-specific complications indiscriminately to every transplant. The word transplant alone does not identify graft source, immune effects, or the child's complete risk profile.
23.How do transplanted stem cells support recovery after intensive treatment?
Blood-forming stem cells can restore marrow production after treatment damages the hematopoietic system. The infusion itself does not immediately normalize circulating cells or immune function. During recovery, the child may remain vulnerable to infection, bleeding, and anemia and require protective and supportive measures. Distinguish stem-cell administration from established recovery of blood-cell production. Follow the clinical course and laboratory trends rather than treating the transplant date as evidence that normal host defenses have already returned.
Apply it
The day after stem-cell infusion, a parent asks to stop infection precautions because new cells have been given. Explain that functional recovery takes time and that current counts and clinical status still guide protective care.
Common pitfall: Infused stem cells do not instantly provide normal neutrophil or platelet levels. Early supportive needs persist even when the cell infusion itself was uncomplicated.
24.How do graft-versus-host and graft-versus-leukemia effects differ?
After allogeneic transplantation, donor immune cells can recognize recipient tissues as foreign. Attack on healthy tissues produces graft-versus-host disease, commonly involving organs such as skin, liver, or gastrointestinal tract. Recognition and destruction of residual leukemia produces a potentially beneficial graft-versus-leukemia effect. These effects share a donor immune basis but have different targets and consequences. New rash, diarrhea, or liver abnormalities need assessment; they should not be interpreted as reassuring evidence that a beneficial antileukemia response is occurring.
Apply it
An allogeneic transplant recipient develops a new rash and persistent diarrhea. Explain that donor immunity can harm healthy tissues as well as attack leukemia, and promptly report the findings for assessment of GVHD and other causes.
Common pitfall: A beneficial graft-versus-leukemia effect does not make symptomatic GVHD desirable or safe to ignore. Similar post-transplant symptoms can also have infectious or treatment-related causes.
25.How do CAR T cells recognize a cancer target?
CAR T-cell therapy modifies T cells to express a chimeric antigen receptor that recognizes a selected target on cells. The engineered cells are expanded and infused to produce an immune attack against target-bearing cancer cells. This is a cellular immunotherapy rather than conventional cytotoxic chemotherapy. Target recognition explains both its antitumor purpose and the need for specialized monitoring of immune toxicities, including cytokine release syndrome. Treatment eligibility and target selection depend on the particular disease and product.
Apply it
A parent calls CAR T-cell therapy another chemotherapy infusion. Explain that the product consists of modified immune cells designed to recognize a target, and connect that mechanism with the planned monitoring for immune-related complications.
Common pitfall: Do not describe CAR T cells as able to recognize every cancer. A receptor's target and the specific treatment indication limit where that product can be useful.
26.Why does external-beam radiation not make a child radioactive?
External-beam radiation directs energy from a machine toward the treatment area. It does not leave a radioactive source inside the child, so ordinary contact after treatment does not expose family members to radiation from the patient. This reassurance applies to external-beam treatment, including proton therapy. Internal sources and radiopharmaceutical treatments have different safety considerations. Establish the actual modality before giving contact advice rather than using the broad word radiation as if it described one universal exposure pattern.
Apply it
A sibling is afraid to hug a child returning from external-beam radiation. Explain that no radioactive source remains in the child's body from that treatment and that ordinary family contact is safe after the session.
Common pitfall: Do not extend external-beam contact reassurance automatically to internal radiation or radiopharmaceutical therapy. Safety teaching must follow the actual treatment modality and its specific instructions.
27.How can proton therapy reduce dose beyond a target?
Protons deposit much of their energy near a selected depth and can reduce radiation delivered beyond the target compared with some photon arrangements. This physical property can help spare nearby normal tissues, a relevant consideration in growing children. It does not mean that normal tissues receive no dose or that late effects are impossible. Treatment planning still depends on tumor location, anatomy, and technical considerations. Explain potential tissue sparing without promising superior outcomes for every pediatric tumor.
Apply it
A parent concludes that proton therapy eliminates all future radiation risks. Explain how its depth-dose properties can reduce selected normal-tissue exposure while emphasizing that the child still needs treatment-specific toxicity assessment and long-term follow-up.
Common pitfall: A favorable physical dose distribution does not guarantee a better clinical outcome in every situation. Proton treatment still requires careful planning and monitoring for adverse effects.
28.What surgical information must be communicated after a Wilms tumor operation?
Wilms tumor surgery provides local tumor control and information that influences subsequent therapy. The operative handoff should identify the resection performed, lymph-node sampling, residual disease, and any tumor rupture or spill. Spill is an oncologic finding that can affect staging and treatment planning, even when immediate recovery is uncomplicated. Nephrectomy also changes the child's renal exposure history and future follow-up needs. Surgical timing and renal preservation decisions vary with the clinical situation. See the [NCI Wilms tumor surgical guidance](https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq).
Apply it
After nephrectomy, the child is stable, but the operative report documents tumor spill. Include this finding in the oncology handoff rather than reporting only successful removal and stable vital signs; ensure the resection details enter the treatment summary.
Common pitfall: An uncomplicated recovery does not establish complete oncologic resection or settle postoperative treatment. Avoid assuming every child with Wilms tumor receives an identical surgical sequence.
CPHON Test Content Outline — currently linked standalone PDF · Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0
Symptom Management and Supportive Care26%
29.How does gentle oral care support a child with mucositis?
Cancer treatment can injure the rapidly renewing oral lining, causing inflammation, ulceration, and pain. Gentle cleaning helps maintain oral hygiene without adding unnecessary trauma. A soft toothbrush and recommended bland rinses are generally preferable to abrasive techniques or irritating alcohol-containing products. Assessment includes pain, lesions, bleeding, and intake. Care should be individualized when complications develop rather than abandoned altogether. The goal is to preserve comfort and oral cleanliness while recognizing when infection, bleeding, or severe symptoms require additional evaluation.
Apply it
A child avoids brushing because the mouth is sore. Assess the mucosa and pain, arrange appropriate symptom relief, and demonstrate gentle cleaning with the recommended products rather than advising complete cessation of oral hygiene.
Common pitfall: Harsh mouthwash may appear stronger but can worsen irritation. Stopping all oral care can also worsen hygiene without addressing the cause of pain or ulceration.
Mouth and Throat Problems: Cancer Treatment Side Effects | NCI
30.When does mucositis threaten hydration and nutrition?
The clinical importance of mucositis extends beyond how the mouth looks. Painful swallowing or extensive ulceration can prevent adequate drinking, eating, and oral medication use. Assess intake, hydration, weight trends, swallowing ability, and pain control together. Soft, nonirritating foods may help when tolerated, but severe functional limitation needs additional support. A child who cannot drink requires more than reassurance or a change in mouthwash. Fever or other infection concerns also change the urgency of assessment.
Apply it
A child has modest visible oral lesions but has taken almost no fluid because swallowing hurts. Escalate assessment of hydration and analgesia and involve the team in a practical intake-support plan rather than grading severity by appearance alone.
Common pitfall: A small number of visible ulcers can cause major functional impairment. Do not wait for dramatic oral findings before responding to inadequate fluid or medication intake.
Mouth and Throat Problems: Cancer Treatment Side Effects | NCI
31.Why does cancer-related fatigue require a search for contributors?
Cancer-related fatigue is persistent exhaustion that can interfere with function and may not resolve with ordinary rest. It can reflect several interacting contributors, including anemia, pain, sleep problems, emotional distress, poor nutrition, treatment effects, or other illness. Assessment should identify changes from baseline and potentially treatable causes rather than assuming fatigue is inevitable. The nursing decision is to connect symptom severity with function, associated findings, and likely contributors before recommending a single generic solution.
Apply it
An adolescent reports new exhaustion and reduced school participation. Assess sleep, pain, intake, mood, medications, and relevant clinical findings, then communicate possible reversible contributors instead of advising the adolescent simply to stay in bed longer.
Common pitfall: Fatigue is common but should not be dismissed as normal. A new or worsening pattern can reveal a treatable problem that extra rest alone will not correct.
32.How can activity and rest be balanced during cancer-related fatigue?
Fatigue management combines attention to contributing conditions with practical energy planning. Appropriate physical activity can support function, while planned rest and prioritization help conserve energy for meaningful tasks. The balance depends on the child's medical status and tolerance; prolonged inactivity is not a universal treatment. Ask which activities matter most and how symptoms change with exertion. A useful plan preserves participation where possible while avoiding demands that exceed current safety limits or obscure a worsening clinical condition.
Apply it
A medically stable teenager spends most days in bed but wants to reconnect with friends. Help plan a brief tolerable activity and rest periods, then reassess symptoms and function rather than prescribing either unrestricted exercise or complete inactivity.
Common pitfall: Do not interpret activity advice as permission to ignore new breathlessness, dizziness, or other concerning symptoms. Medical stability and individual tolerance determine what is appropriate.
33.Why can nausea begin before chemotherapy is administered?
Anticipatory nausea can develop through conditioning when treatment-associated sights, smells, sounds, or settings become linked with previous nausea and vomiting. Symptoms may begin before a drug is given, so timing helps distinguish this pattern from acute post-treatment nausea. Prevention of earlier uncontrolled symptoms is important. Once established, anticipatory symptoms may benefit from behavioral approaches alongside the overall antiemetic plan. The child is experiencing a learned physiological response, not deliberately producing symptoms or proving that treatment is unnecessary.
Apply it
A child becomes nauseated when entering the infusion room before any medication is administered. Explore the consistent environmental trigger, review prior symptom control, and involve the team in behavioral strategies and the broader nausea-management plan.
Common pitfall: Calling the symptom imaginary damages trust and misses the conditioned mechanism. Giving the same response to every nausea pattern also overlooks the importance of timing.
34.Why should antiemetic planning distinguish prevention from rescue?
Antiemetic prevention aims to reduce nausea and vomiting before they occur, while rescue treatment addresses symptoms that develop despite the planned regimen. Acute, delayed, and anticipatory patterns have different timing and may require different strategies. Document when symptoms start, how long they persist, intake effects, and response to medication. Waiting for severe vomiting before every intervention can allow dehydration and reinforce anticipatory symptoms. Medication choice and scheduling should follow the child's treatment-specific plan rather than an adult dosing template.
Apply it
A child vomits at home the day after each cycle despite feeling well during infusion. Record the delayed pattern and contact the team to review prevention and rescue instructions instead of assuming the infusion-day plan covers every period.
Common pitfall: Absence of vomiting during treatment does not establish adequate control afterward. Delayed nausea and reduced intake still require assessment even when no emesis occurs.
35.How should persistent pain guide interdisciplinary supportive care?
Persistent pain requires assessment of location, quality, timing, functional impact, associated symptoms, and response to previous measures. Cancer, procedures, treatment effects, and unrelated conditions can produce different pain mechanisms. Palliative care can help coordinate medication and nonmedication strategies while disease-directed treatment continues. Reassessment is essential because reduced distress or sleep alone does not fully describe functional recovery. New focal or rapidly changing pain also needs evaluation for a new complication rather than automatic escalation of an existing symptom plan.
Apply it
A child sleeps after analgesia but still cannot walk comfortably or participate in play. Reassess pain and function, communicate the incomplete response, and involve the relevant team members in refining the plan and investigating its cause.
Common pitfall: Quiet behavior does not prove adequate relief. Sedation, fear, developmental differences, or exhaustion can reduce visible distress while clinically important pain remains present and limits function.
36.Which functional changes suggest vincristine-related neuropathy?
Vincristine can injure peripheral nerves, producing motor, sensory, or autonomic problems. Weakness, altered gait, foot drop, reduced dexterity, abnormal sensations, and bowel difficulties can affect ordinary activities. Functional questions may reveal toxicity before a child can describe a neurological symptom clearly. Ask about stairs, falls, handwriting, dressing, and bowel habits, and compare with baseline. Report new findings for assessment rather than assuming that reduced participation reflects poor effort, normal fatigue, or an unavoidable permanent disability.
Apply it
A child receiving vincristine begins tripping and needs help fastening clothes. Assess the change from baseline and report possible peripheral neuropathy, while arranging appropriate mobility and occupational support rather than attributing both problems to reluctance.
Common pitfall: Neuropathy is not limited to tingling. Motor and autonomic effects can be clinically important even when the child denies numbness or cannot describe sensory changes.
Late Effects of Treatment for Childhood Cancer (PDQ) — Health Professional Version | NCI
37.Why can cardiac surveillance remain important after anthracycline exposure?
Anthracycline exposure can increase the risk of later cardiac dysfunction, and relevant radiation exposure can modify cardiac risk. Clinical symptoms may appear after a long interval, so follow-up is based on treatment exposure and guideline-defined risk rather than current appearance alone. The nurse should preserve accurate exposure records, reinforce individualized surveillance, and assess new exercise intolerance, breathlessness, or other concerning changes. A normal prior study does not mean that all future exposure-related cardiac risk has ended.
Apply it
A survivor feels well and wants to discontinue cardiac follow-up after a normal assessment. Review the anthracycline exposure and explain why the individualized surveillance plan continues, while reinforcing prompt reporting of new exercise intolerance or breathing changes.
Common pitfall: Do not invent one cardiac screening interval for every survivor. Exposure details and guideline risk categories determine surveillance, while symptoms require evaluation regardless of the calendar.
Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0
38.How can treatment-related hearing loss affect school performance?
Platinum chemotherapy and certain radiation exposures can increase the risk of hearing impairment. A child may miss speech or classroom instructions without reporting obvious deafness, and high-frequency deficits can be especially difficult for families to recognize. Apparent inattention or declining performance should prompt consideration of auditory function and exposure history. Follow-up can include formal hearing assessment and educational support. The decision depends on both treatment risk and function, rather than waiting until the child cannot hear ordinary conversation.
Apply it
A platinum-exposed survivor is described as inattentive and repeatedly misses spoken instructions. Ask about hearing and classroom conditions, review the follow-up plan, and coordinate audiology assessment and appropriate school support rather than assuming a behavioral problem.
Common pitfall: Successful conversation in a quiet clinic does not exclude hearing difficulty in a noisy classroom. Functional context matters when evaluating apparent attention or learning concerns.
Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0
39.How can ifosfamide-related tubular injury escape a creatinine-only assessment?
Ifosfamide can cause glomerular injury and tubular dysfunction, including Fanconi syndrome. Creatinine mainly informs filtration; tubular injury can impair reabsorption and cause electrolyte or bicarbonate wasting despite a reassuring creatinine. Phosphate loss can contribute to bone disease. Renal assessment therefore includes blood pressure and exposure-appropriate electrolytes as well as renal-function measures.
Apply it
An ifosfamide-exposed survivor has low phosphate and bicarbonate with stable creatinine. Consider tubular wasting and report the pattern for renal assessment rather than declaring kidney function normal from creatinine alone.
Common pitfall: Reduced filtration and defective tubular reabsorption are different injury patterns; one test cannot exclude both.
Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0
40.Why should poor growth after hypothalamic-pituitary radiation prompt endocrine evaluation?
Radiation involving the hypothalamic-pituitary axis can impair growth hormone secretion. Serial growth velocity identifies slowing that one acceptable height percentile can miss. Assess pubertal stage, nutrition, and thyroid function in a poorly growing survivor; hypothyroidism can also impair growth. Hypothalamic-pituitary injury can cause central hypothyroidism, making free T4 important alongside TSH.
Apply it
An irradiated survivor falls across height percentiles. Document serial growth and puberty, review the radiation field, and coordinate endocrine evaluation including thyroid assessment.
Common pitfall: Neither short stature nor normal TSH alone establishes the cause of poor growth.
Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0
41.When should fertility preservation be discussed before gonadotoxic treatment?
Potential fertility effects should be discussed before treatment that may damage reproductive function, because some preservation options require action before exposure. The discussion must consider the planned therapy, urgency, developmental status, available methods, and the patient's preferences. For patients with ovaries, options and feasibility differ with age and clinical circumstances. Early specialist referral supports an informed decision without promising preservation success or delaying urgent therapy without coordinated consideration. Infertility risk is individualized rather than inferred solely from the cancer diagnosis.
Apply it
An adolescent with ovaries is scheduled for potentially gonadotoxic therapy. Promptly request fertility counseling before treatment begins, explain that options depend on timing and clinical circumstances, and include the adolescent's questions in the coordinated discussion.
Common pitfall: Waiting until treatment is complete can remove some preservation opportunities. Do not guarantee infertility, preservation success, or equal suitability of every method for every child.
42.How does aseptic connector access reduce catheter infection risk?
A catheter connector can introduce organisms into the bloodstream when contaminated surfaces are accessed. Hand hygiene, aseptic technique, appropriate connector disinfection, and sterile access devices reduce that opportunity. An intact dressing protects the insertion site but does not replace safe hub handling. Evaluate the entire access sequence rather than one visible component. Product-specific technique matters, and the process must be repeated when access occurs; a clean appearance alone does not establish that a connector is free of microorganisms.
Apply it
A caregiver believes an implanted device needs no connector cleaning because its dressing is intact. Demonstrate the prescribed access sequence and explain how contamination at the connector can enter the bloodstream despite a protected insertion site.
Common pitfall: Wearing gloves does not replace hand hygiene or connector disinfection. A visually clean hub and an intact dressing address different parts of catheter infection prevention.
Summary of Recommendations — Intravascular Catheter-Related Infections | CDC
43.What is the first response to a suspected transfusion reaction?
Stop the transfusion promptly when a reaction is suspected, assess the patient's condition and vital signs, and obtain urgent assistance according to severity. Maintain appropriate vascular access without flushing residual implicated blood into the patient, verify identification details, and notify the responsible clinician and transfusion service. Fever, rigors, breathing difficulty, pain, hypotension, or other new findings may have different causes. Initial safety actions precede confident classification; a nurse should not continue the transfusion while waiting to identify the reaction precisely.
Apply it
During a red-cell transfusion, a child develops rigors and new breathing difficulty. Stop the transfusion, initiate immediate assessment and assistance, and notify the clinical and transfusion teams while preserving the product and administration materials for evaluation.
Common pitfall: Simply slowing the infusion can prolong exposure to a harmful product. Do not label a reaction minor before assessing respiratory and circulatory status and excluding serious causes.
Management of suspected reactions | Australian Red Cross Lifeblood
Pediatric Hematologic and Oncologic Emergencies21%
44.How do risk classification and clinical stability guide febrile-neutropenia treatment?
Use a validated pediatric risk-stratification strategy. High-risk episodes require prompt empiric antipseudomonal antibacterial monotherapy: an appropriate beta-lactam, fourth-generation cephalosporin, or carbapenem. Additional Gram-negative coverage or a glycopeptide is reserved for instability, suspected resistance, or substantial local resistance. Obtain cultures from all central lumens and consider peripheral cultures without delaying urgent treatment. Selected low-risk patients may receive outpatient care through a program ensuring monitoring, reliable team contact, prompt return, and medication access; oral therapy also requires reliable tolerance. Local fever definitions are separate from these treatment principles.
Apply it
A comfortable child still needs formal risk assessment. If outpatient care is considered, verify follow-up and rapid-return arrangements. Begin treatment and stabilization immediately for instability.
Common pitfall: Well appearance alone does not establish low risk. Persistent fever alone in a stable patient does not automatically require broader antibacterial coverage.
45.Why does abdominal pain during neutropenia raise concern for typhlitis?
Typhlitis, or neutropenic enterocolitis, involves bowel inflammation in the setting of impaired host defense and often chemotherapy-related mucosal injury. Fever with abdominal pain, tenderness, distension, diarrhea, or gastrointestinal bleeding warrants urgent evaluation. Bowel-wall thickening on ultrasound or CT supports the diagnosis. Initial management commonly includes broad-spectrum antibiotics, fluid and nutritional support, and bowel rest when clinically indicated; deterioration or suspected perforation requires urgent surgical assessment. See the [pediatric enterocolitis study](https://pubmed.ncbi.nlm.nih.gov/21910749/) and [pediatric surgical outcomes study](https://pubmed.ncbi.nlm.nih.gov/19231539/).
Apply it
A neutropenic child develops fever and worsening abdominal tenderness after chemotherapy. Escalate for sepsis and abdominal assessment, support timely imaging and antimicrobial treatment, and report increasing distension, bleeding, or circulatory deterioration.
Common pitfall: Do not assume abdominal pain is routine nausea or constipation. Typhlitis can coexist with other abdominal disease, and perforation or another surgical cause must remain under consideration.
CPHON Test Content Outline — currently linked standalone PDF · Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update
46.How does tumor lysis produce its characteristic biochemical pattern?
Rapid malignant-cell destruction releases potassium, phosphate, and nucleic acids. Purine breakdown raises uric acid; phosphate binding and precipitation can lower calcium. Hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia can accompany kidney injury, which further impairs clearance. Risk increases with bulky, rapidly proliferating, treatment-sensitive disease and impaired renal function; spontaneous lysis is also possible. Prevention combines prescribed hydration, uric-acid management, serial laboratory assessment, and accurate fluid balance. Falling output or fluid accumulation requires reassessment rather than automatic additional fluid.
Apply it
After treatment starts, potassium and phosphate rise, calcium falls, and urine output declines. Report the coordinated trends immediately, assess cardiac and neurological status, and review renal clearance and fluid tolerance.
Common pitfall: Do not wait for every classic abnormality. A normal component does not exclude evolving lysis, and improvement in uric acid does not establish resolution of the other risks.
47.Why can a mediastinal mass become dangerous during positioning or sedation?
A mediastinal mass can compress the trachea or major bronchi and may compromise cardiovascular structures. Orthopnea, stridor, wheeze, collapse, or upper-body congestion are warning findings. Supine positioning and sedation or anesthesia can precipitate critical deterioration in a child with compression. Preserve the position of comfort and obtain urgent oncology, anesthesia, and intensive-care involvement before procedures. Imaging requiring the child to lie flat must be considered within this risk assessment. See the [Royal Children's Hospital mediastinal-mass guideline](https://www.rch.org.au/clinicalguide/guideline_index/Oncological_emergencies__Mediastinal_mass/).
Apply it
A child with a mediastinal mass becomes breathless when lying back for imaging. Restore the tolerated position, escalate urgently, and obtain a coordinated procedural plan rather than administering sedation to overcome difficulty lying flat.
Common pitfall: Inability to lie flat can signal mechanical compromise. Treating it only as anxiety can expose the child to a hazardous position or anesthetic.
CPHON Test Content Outline — currently linked standalone PDF
48.How can paraspinal neuroblastoma cause a neurological emergency?
Neuroblastoma arising near the spine can extend through neural foramina and compress the spinal cord. New weakness, impaired walking, or evolving paralysis requires immediate assessment; MRI evaluates threatening paraspinal extension. Neurological recovery depends partly on the severity and duration of deficits, so treatment should precede advanced deterioration. Neuroblastoma-related compression may respond to urgent chemotherapy; severe or worsening compression can require neurosurgical intervention. The response is disease-specific rather than automatic use of one treatment for every cord-compression case. See the [NCI neuroblastoma guidance](https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq).
Apply it
A child with paraspinal neuroblastoma begins dragging a foot and needs help walking. Document the neurological change and urgently activate oncology assessment and spinal imaging rather than waiting for the next scheduled tumor evaluation.
Common pitfall: Do not wait for complete paralysis or assume new weakness is treatment-related fatigue. Delayed recognition can reduce the chance of neurological recovery.
CPHON Test Content Outline — currently linked standalone PDF
49.How do uric-acid mechanisms determine rasburicase safety and specimen handling?
Allopurinol inhibits xanthine oxidase to reduce new uric-acid formation. Rasburicase converts existing uric acid to more soluble allantoin and generates hydrogen peroxide. It is contraindicated in G6PD deficiency because oxidative injury can cause hemolysis; screen patients at higher risk before treatment. Serious hypersensitivity, hemolysis, or methemoglobinemia requires immediate permanent discontinuation. Rasburicase remains active in collected blood and can cause falsely low uric-acid results. Collect specimens in prechilled heparin tubes, immediately maintain them in an ice-water bath, prepare plasma using a precooled centrifuge at 4°C, and keep plasma chilled until analysis within four hours of collection.
Apply it
A post-rasburicase uric-acid specimen sat at room temperature. Report the handling problem and arrange correctly handled sampling rather than interpreting the low result as proof that the uric-acid burden has resolved.
Common pitfall: Drug activity in the tube can mimic clinical improvement. Correct specimen handling and G6PD safety checks address different hazards, and neither replaces monitoring of the other tumor-lysis abnormalities.
DailyMed - ELITEK- rasburicase kit · Prevention of tumour lysis syndrome | eviQ
50.Which respiratory changes suggest acute chest syndrome in sickle cell disease?
Acute chest syndrome is a potentially life-threatening sickle cell complication. Diagnostic criteria include a new pulmonary infiltrate involving at least one lung segment, inconsistent with atelectasis, plus at least one compatible finding such as chest pain, fever, respiratory symptoms, or hypoxemia relative to baseline. Symptoms without an infiltrate still require close assessment for evolving disease. Infection can contribute to the syndrome, so pneumonia and acute chest syndrome are not mutually exclusive. New respiratory findings during a pain admission require urgent reassessment.
Apply it
A child admitted for limb pain develops cough, fever, and falling oxygen saturation. Escalate promptly, support oxygenation and chest imaging, and assess for acute chest syndrome and infectious contributors rather than attributing the changes to the original pain episode.
Common pitfall: Do not wait for severe chest pain or use an initially nondiagnostic image to dismiss subsequent deterioration. Reassessment follows the evolving respiratory course.
Sickle Cell Disease — How Sickle Cell Disease May Affect Your Health | NHLBI · Sickle Cell and Acute Chest Syndrome Clinical Pathway – Inpatient | Children's Hospital of Philadelphia
51.Why can splenic sequestration cause rapid circulatory deterioration?
Splenic sequestration traps a substantial volume of blood in the spleen, causing enlargement, an acute hemoglobin decline, and reduced circulating volume. Pallor, weakness, tachycardia, or signs of shock can accompany the change. The combination of a newly enlarged spleen and acute deterioration is especially important in a child with sickle cell disease. This is different from stable chronic anemia. Urgent evaluation and treatment are required because the circulatory consequence can become dangerous before a family recognizes the full severity.
Apply it
A young child with sickle cell disease becomes abruptly pale and weak, and the caregiver reports a larger abdomen. Assess urgently for splenic enlargement and circulatory compromise and activate emergency evaluation instead of attributing the change to baseline anemia.
Common pitfall: Do not normalize a sudden decline because chronic anemia is expected in sickle cell disease. A changing spleen and perfusion findings indicate a different, urgent process.
Sickle Cell Disease — How Sickle Cell Disease May Affect Your Health | NHLBI
52.When do neurological symptoms in sickle cell disease require emergency action?
Sickle cell disease increases stroke risk, and sudden weakness, facial asymmetry, speech difficulty, vision change, seizures, or other acute neurological findings require emergency evaluation. A transient improvement does not make the episode harmless. The nursing priority is rapid recognition and activation of acute care, with attention to symptom onset and current neurological status. Disease-specific treatment is time-sensitive and requires specialist coordination. A history of migraine, pain, or prior similar symptoms should not substitute for evaluation of a possible new cerebrovascular event.
Apply it
A child with sickle cell disease develops slurred speech and one-sided arm weakness that partially improves before arrival. Record onset details and activate emergency stroke assessment rather than waiting to see whether the symptoms disappear completely.
Common pitfall: Improvement does not exclude a serious vascular event. Do not attribute focal deficits to fatigue, medication, or anxiety without urgent assessment of the possible neurological emergency.
Sickle Cell Disease — How Sickle Cell Disease May Affect Your Health | NHLBI · Sickle Cell Disease — Treatment | NHLBI
53.What is the immediate response to suspected vincristine extravasation?
Stop administration immediately, disconnect the infusion tubing, and obtain assistance. Initially leave the access device in place so residual drug can be gently aspirated through it; do not flush, because flushing can drive additional vincristine into surrounding tissue. Assess pain, swelling, skin changes, and distal neurovascular function, then mark, measure, photograph, and document the affected area. Implement vincristine-specific management with prescribed hyaluronidase and moderate warmth to promote drug dispersion. Initial device precautions are supported by the [eviQ extravasation algorithm](https://www.eviq.org.au/getmedia/7aa4791d-67f4-498f-b052-dd4b150270f8/ID-1078-Algorithm-extravasation-management.pdf.aspx?ext=.pdf) and [RCH pediatric guidance](https://www.rch.org.au/clinicalguide/guideline_index/peripheral_extravasation_injuries/).
Apply it
A child reports burning and develops swelling around a peripheral catheter during vincristine administration. Stop and disconnect the infusion, call for help, retain the catheter initially for gentle aspiration, and do not flush. After aspiration, remove the peripheral catheter as directed by the extravasation pathway. Suspected central-device extravasation requires specialist assessment of device integrity and the extent of leakage before removal or reuse. Any remaining prescribed dose requires assessment and verified intact access at another site.
Common pitfall: Removing the catheter immediately sacrifices an opportunity to aspirate residual drug. Slowing the infusion or flushing to test patency prolongs tissue exposure. Cold compresses are not interchangeable with the moderate warmth used for vincristine. Continue reassessment because an initially small area of swelling does not establish the final extent of injury.
DailyMed - VINCRISTINE SULFATE injection, solution · CPHON Test Content Outline — currently linked standalone PDF
54.Which joint findings suggest hemarthrosis in a child with hemophilia, and what action follows?
Hemarthrosis is bleeding into a joint. Pain, warmth, swelling, stiffness, and reduced movement are characteristic findings; pain or a sensation of tightness may precede obvious swelling. Bleeding can occur after minor activity or without recognized trauma, and intact skin does not exclude it. Hemophilia A involves factor VIII deficiency, whereas hemophilia B involves factor IX deficiency. Prompt hemostatic treatment using the child's prescribed bleeding plan is essential because recurrent joint bleeding can cause chronic inflammation, cartilage damage, and lasting loss of function.
Apply it
A child with hemophilia develops knee warmth and pain after ordinary play and refuses to bend the knee. Suspect hemarthrosis, protect the joint from further stress, assess pain and neurovascular status, and promptly initiate the prescribed hemostatic treatment pathway. When factor replacement is prescribed, the product must match the deficient factor. Record symptom onset and changes in swelling and movement so subsequent assessments can identify improvement or continued bleeding.
Common pitfall: Waiting for a bruise, major trauma, or marked swelling can delay treatment of internal bleeding. Repeatedly forcing the joint through its range of motion or encouraging walking can worsen pain and stress the bleeding joint. Protection and comfort measures support care but do not replace the hemostatic treatment needed to control hemorrhage.
55.Why are fever and hypotension after CAR T-cell therapy concerning?
Activated immune cells can release large amounts of cytokines after CAR T-cell therapy, producing cytokine release syndrome. Fever can accompany hypotension, hypoxemia, and organ dysfunction. These findings require urgent assessment and severity-based management. They can overlap with infection, so timing after cellular therapy does not establish a single diagnosis. The nursing decision is to recognize the dangerous physiological pattern, escalate promptly, and support evaluation for both immune toxicity and infectious causes rather than observing for spontaneous resolution.
Apply it
After CAR T-cell infusion, a child develops fever, falling blood pressure, and an oxygen requirement. Activate urgent assessment for cytokine release syndrome and infection, communicate the treatment timing, and support immediate stabilization under the cellular therapy pathway.
Common pitfall: Do not label post-CAR T fever automatically as expected or noninfectious. Cytokine toxicity and infection can produce overlapping signs and may require simultaneous evaluation.
Psychosocial Dimensions of Care8%
56.How can school coordination preserve participation during treatment?
Treatment can interrupt attendance, concentration, peer contact, and ordinary routines. School coordination helps translate the child's medical and functional needs into an individualized participation plan. Communication should address practical limitations and support needs while respecting the family's preferences about sharing information. The aim is continued learning and connection rather than waiting for complete recovery before any engagement. Reassess as treatment intensity and function change, because a plan appropriate during one phase may become unnecessarily restrictive or insufficient during another.
Apply it
A child misses frequent classes and feels excluded from friends. With family agreement, coordinate communication with school staff about learning access, manageable participation, and peer connection, then review the plan as symptoms and attendance change.
Common pitfall: A blanket instruction to avoid school throughout treatment can unnecessarily increase isolation. Conversely, returning physically does not ensure that learning and social support needs have been addressed.
57.How should procedure preparation change with developmental understanding?
Children understand illness and procedures differently according to developmental level, prior experience, and individual communication needs. Clear explanations should describe what the child will experience using language and preparation methods the child can understand. Honest, manageable information supports trust; promises that a painful procedure will not hurt can undermine it. Invite questions and offer genuine choices where available, while distinguishing those choices from essential treatment requirements. Preparation should be individualized rather than determined by chronological age alone.
Apply it
A young child asks whether a needle procedure will hurt. Give a brief honest explanation, describe the planned comfort measures, and offer a real choice such as a coping activity rather than promising that nothing will be felt.
Common pitfall: Too much technical detail can overwhelm, while false reassurance can damage trust. A choice is only helpful when staff can actually honor the child's selected option.
58.Why should siblings be asked directly about guilt and isolation?
Siblings may experience fear, jealousy, guilt, loneliness, and changes in family attention when a brother or sister has cancer. Some mistakenly believe their thoughts, arguments, or actions caused the illness. Direct, age-appropriate discussion can correct these beliefs and identify unmet support needs. Maintaining social connections and ordinary activities can help, alongside opportunities to ask questions. A sibling who appears independent or helpful may still be distressed, so visible behavior should not be the only basis for deciding whether support is needed.
Apply it
A sibling says the cancer began after an argument and asks whether apologizing will cure it. Clearly state that the argument did not cause the illness, invite further questions, and help preserve supportive routines and social contact.
Common pitfall: Praising a sibling only for being strong or undemanding can discourage disclosure. Distress deserves attention even when it is less visible than the patient's treatment needs.
Support for siblings when a brother or sister has cancer | NCI
59.How can practical barriers be distinguished from lack of engagement?
Missed visits, delayed refills, or difficulty following instructions may reflect transportation problems, work demands, financial strain, competing caregiving responsibilities, or misunderstanding. A nonjudgmental assessment identifies the actual barrier before assigning motivation. Families may need social work, navigation, clearer teaching, or coordination across services rather than repeated reminders alone. The nursing decision is to ask what makes the plan difficult, confirm understanding, and connect the family with relevant assistance while maintaining attention to the child's immediate treatment and safety needs.
Apply it
A caregiver repeatedly misses early appointments because public transport does not arrive in time and job loss is threatened. Document the specific barriers and coordinate practical assistance and scheduling discussion rather than labeling the caregiver uninterested in treatment.
Common pitfall: An adherence label can conceal a solvable access problem. Education alone cannot resolve transportation, employment, or financial barriers when the family already understands the clinical plan.
60.How can nurses support family preferences while preserving the child's voice?
Family-centered care includes understanding who provides support, how information is shared, and which cultural, spiritual, or personal preferences matter to the family. The child or adolescent also needs developmentally appropriate opportunities to express concerns and preferences. Ask rather than infer beliefs from appearance or background. Individualized communication can reveal different needs within one family. Preferences should inform a coordinated care discussion while the team addresses clinical requirements and relevant consent rules rather than assuming one family member speaks for every concern.
Apply it
During planning, a caregiver answers every question while the adolescent remains silent. Invite the adolescent's perspective in an appropriate, respectful manner and ask how the family prefers information and support to be shared during ongoing care.
Common pitfall: Cultural sensitivity does not mean assuming uniform beliefs or overlooking the child's questions. Family agreement on a broad plan can coexist with individual concerns needing attention.
Support for Families: Childhood Cancer | NCI · CPHON Test Content Outline — currently linked standalone PDF
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give the greatest combined study attention to supportive care, treatment effects, and emergencies, while retaining all six official domains.
- Practise discriminating pairs: remission versus MRD negativity, autologous versus allogeneic grafts, GVHD versus graft-versus-leukemia, and external-beam versus internal radiation precautions.
- Connect presentations and procedures to mechanisms: solid-tumor mass effects, biopsy planning, surgical findings, marrow suppression, coagulation deficiencies, and medication-route safeguards.
- Recognize additional emergency patterns: typhlitis, mediastinal compression, spinal cord compression, extravasation, tumor lysis, sickle cell complications, and immune toxicity.
- Link survivorship surveillance to documented exposures, including ifosfamide tubular injury and hypothalamic-pituitary endocrine dysfunction.
- Integrate consent, development, family communication, school participation, and practical access barriers into clinical decisions.
- Use the full official outline to extend review into emergencies, procedures, therapies, and system-specific effects beyond this selective guide.
A practical preparation plan
1. Map your clinical experience to the six domains
Read the current CPHON outline and mark each subtopic as familiar, partly familiar, or unfamiliar. Identify gaps created by your practice setting, especially nonmalignant hematology for oncology-focused nurses and oncology treatment effects for hematology-focused nurses.
2. Build mechanism-to-action explanations
For each concept, explain the mechanism, decisive clinical cue, appropriate response, and boundary of the recommendation. Practise with paired findings such as fever with neutropenia, new hypoxemia during sickle pain, orthopnea with a mediastinal mass, and weakness with a paraspinal tumor.
3. Allocate review by weight and weakness
Use the published domain weights as the starting point, then add time to your weakest areas. Ensure that the smaller Care Continuum and Psychosocial Dimensions of Care domains retain planned review rather than being left until the end.
4. Complete the questions before reading explanations
Choose one answer for each drill and record the cue that determined your choice. Review every alternative afterward. Classify errors as missing knowledge, missed clinical cue, mechanism confusion, or an unsupported assumption, and target the next review accordingly.
5. Use spaced recall and complete the scope
Revisit flashcards until you can provide the reasoning as well as the term. Return to the official outline to study omitted subtopics with current pediatric resources. Use ONCC's practice materials to become familiar with the verified examination format.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Certified Pediatric Hematology Oncology Nurse (CPHON®) | ONCC
- Prepare for test | ONCC
- 2026 ONCC Certification Test Registration Manual
- CPHON Test Content Outline — currently linked standalone PDF
- CPHON Test Content Outline — Effective 2023
- Care for Childhood Cancer Survivors | NCI
- Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0
- About Hemophilia | CDC
- Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) — Health Professional Version | NCI
- How Do Clinical Trials Work? | NCI
- Are Clinical Trials Safe? | NCI
- Sickle Cell Disease — Treatment | NHLBI
- Sickle Cell Disease — How Sickle Cell Disease May Affect Your Health | NHLBI
- Stem Cell Transplants in Cancer Treatment | NCI
- T-cell Transfer Therapy | NCI
- External Beam Radiation Therapy for Cancer | NCI
- Mouth and Throat Problems: Cancer Treatment Side Effects | NCI
- Palliative Care in Cancer | NCI
- Management of suspected reactions | Australian Red Cross Lifeblood
- Late Effects of Treatment for Childhood Cancer (PDQ) — Health Professional Version | NCI
- Female Fertility and Cancer Treatment | NCI
- Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update
- Prevention of tumour lysis syndrome | eviQ
- Support for Families: Childhood Cancer | NCI
- Support for siblings when a brother or sister has cancer | NCI
- Summary of Recommendations — Intravascular Catheter-Related Infections | CDC
- Cancer Fatigue | NCI
- Nausea and Vomiting and Cancer | NCI
- DailyMed - ELITEK- rasburicase kit
- DailyMed - VINCRISTINE SULFATE injection, solution
- Sickle Cell and Acute Chest Syndrome Clinical Pathway – Inpatient | Children's Hospital of Philadelphia
- Wilms Tumor - NCI
- Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®) - NCI
- Osteosarcoma and UPS of Bone Treatment - NCI
- Osteosarcoma and UPS of Bone Treatment (PDQ®) - NCI
- Neuroblastoma Treatment (PDQ®) - NCI
- Management of neutropenic enterocolitis in children with cancer - PubMed
- 4156-Extravasation management- Clinical procedure | eviQ
- Clinical Practice Guidelines : Peripheral extravasation injuries: Initial management and washout procedure
- Clinical Practice Guidelines : Oncological emergencies: Mediastinal mass
- Diagnosis, incidence, and outcomes of suspected typhlitis in oncology patients--experience in a tertiary pediatric surgical center in the United Kingdom - PubMed
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.